Hum. Reprod. Advance Access originally published online on March 14, 2006
Human Reproduction 2006 21(6):1408-1415; doi:10.1093/humrep/del030
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study
1 Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands, 2 Hôpital Jean Verdier, Reproductive Medicine Center, University Paris XIII, Paris, France, 3 Universite Catholique de Louvain, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, 4 Allgemeines Krankenhaus, Universitätsklinik für Frauenheilkunde Abteilung Gynäkologischen Endocrinologie und Reproduktions Medicin Spitalgasse 23, Vienna, Austria, 5 Tour Belledonne, Boulevard Maréchal Leclerc 23, Grenoble, 6 Polyclinique Hotel Dieu, Boulevard Charles-de-Gaulle 13, Clermont-Ferrand, France, 7 Kinderwunschzentrum Wien, Lazarettgasse 16–18, Vienna, Austria and 8 University Hospital Nijmegen, AZ St Radboud, Obstetrecs-Gynaecology, Geert Grootenplein Zuid 1b, GA Nijmegen, The Netherlands
9 To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre, PO Box 7075, 1007 MB Amsterdam, The Netherlands. E-mail: cb.lambalk{at}vumc.nl
BACKGROUND: The aim of this study was to assess the non-inferiority of an oral contraceptive (OC)-pretreated cetrorelix regimen and a buserelin regimen in IVF/ICSI patients treated with r-hFSH in terms of total number of oocytes retrieved. METHODS: Multicentre, randomized study. One hundred and eighty two patients were randomized to receive cetrorelix with OC pretreatment (n = 91) or to receive buserelin (n = 91). The cetrorelix group started with daily OCs on cycle day 5 and continued for 21–28 days. Cetrorelix (0.25 mg) was given daily from stimulation day 6 up to and including the day of r-hCG administration. The buserelin group started with buserelin (500 µg/day) for at least 10 days until down-regulation was achieved, after which the dose was reduced to daily 200 µg up to and including the day of r-hCG administration. r-hFSH was started in both groups on a Friday, in the cetrorelix group 5 days after the last OC pill intake. Both regimens were followed by a standard IVF or ICSI procedure. The primary efficacy endpoint was the number of oocytes retrieved per patient. RESULTS: Number of oocytes, cancellation rates, r-hFSH requirements, number of oocyte retrievals during the weekend or public holiday and number of pregnancies were similar in both groups. Both treatment regimens were well tolerated. CONCLUSIONS: Cetrorelix pretreated with OCs resulted in similar number of oocytes retrieved compared with a long buserelin protocol. Both regimens were well tolerated and allowed scheduling of the oocyte retrieval, with only small number of retrievals falling on a weekend or public holiday.
Key words: GnRH agonist/GnRH antagonist/IVF/oral contraceptive/programming
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. G. BROMER, M. B. CETINKAYA, and A. ARICI Pretreatments before the Induction of Ovulation in Assisted Reproduction Technologies: Evidence-based Medicine in 2007 Ann. N.Y. Acad. Sci., April 1, 2008; 1127(1): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.A. Huirne, R. Homburg, and C.B. Lambalk Are GnRH antagonists comparable to agonists for use in IVF? Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cedrin-Durnerin, B. Bstandig, I. Parneix, V. Bied-Damon, C. Avril, C. Decanter, and J.N. Hugues Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol Hum. Reprod., January 1, 2007; 22(1): 109 - 116. [Abstract] [Full Text] [PDF]
|
|